Permira-backed Quotient Sciences, the drug development and manufacturing accelerator, completed the acquisition of Arcinova, a multiservice contract development and manufacturing organization, from investment firm BGF. Financial terms were not disclosed. "Since inception, we set out to build a unique organization that accelerates the development of new medicines for patients in need. We are delighted to move on to the next stage with Quotient as the perfect partner for Arcinova. Deep science, agility, flexibility and the drive for customer service excellence are the cornerstones of both businesses. I look forward to working with the Quotient team and Permira to deliver even greater value for our customers," Ian Shott, Arcinova Co-Founder and Executive Chairman.